JP2011519828A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011519828A5 JP2011519828A5 JP2011505037A JP2011505037A JP2011519828A5 JP 2011519828 A5 JP2011519828 A5 JP 2011519828A5 JP 2011505037 A JP2011505037 A JP 2011505037A JP 2011505037 A JP2011505037 A JP 2011505037A JP 2011519828 A5 JP2011519828 A5 JP 2011519828A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- receptor
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 40
- 102000008234 Toll-like receptor 5 Human genes 0.000 claims description 13
- 108010060812 Toll-like receptor 5 Proteins 0.000 claims description 13
- 238000003780 insertion Methods 0.000 claims description 6
- 102000037240 fusion proteins Human genes 0.000 claims description 3
- 108020001507 fusion proteins Proteins 0.000 claims description 3
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 239000000427 antigen Substances 0.000 claims 5
- 102000038129 antigens Human genes 0.000 claims 5
- 108091007172 antigens Proteins 0.000 claims 5
- 229920001184 polypeptide Polymers 0.000 claims 4
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 102000002689 toll-like receptors Human genes 0.000 claims 1
- 108020000411 toll-like receptors Proteins 0.000 claims 1
- 239000000203 mixture Substances 0.000 description 1
Description
一実施形態では、本発明は、任意の挿入または配列番号２９からの任意の欠失を含めて配列番号２９（Ｒ３コンストラクト）に示す連続的なアミノ酸配列との同一性が少なくとも約５０．０％のアミノ酸配列であって、単離されたアミノ酸配列がＴｏｌｌ様受容体５を活性化する、アミノ酸配列である。
もうひとつの実施形態では、本発明は、任意の挿入または配列番号３０からの任意の欠失を含めて配列番号３０（Ｒ３Ｄ０コンストラクト）に示す連続的なアミノ酸配列との同一性が少なくとも約５０．０％のアミノ酸配列であって、単離されたアミノ酸配列がＴｏｌｌ様受容体５を活性化する、アミノ酸配列である。
さらに別の実施形態では、本発明は、任意の挿入または配列番号３１からの任意の欠失を含めて配列番号３１（Ｄ３Ｎコンストラクト）に示す連続的なアミノ酸配列との同一性が少なくとも約６０．０％のアミノ酸配列であって、単離されたアミノ酸配列がＴｏｌｌ様受容体５を活性化する、アミノ酸配列である。
本発明の別の実施形態は、任意の挿入または配列番号３２からの任意の欠失を含めて配列番号３２（Ｄ３ＮＣｓコンストラクト）に示す連続的なアミノ酸配列との同一性が少なくとも約６０．０％のアミノ酸配列であって、単離されたアミノ酸配列がＴｏｌｌ様受容体５を活性化する、アミノ酸配列である。
一実施形態では、本発明は、任意の挿入または配列番号２９からの任意の欠失を含めて配列番号２９（Ｒ３コンストラクト）に示す連続的なアミノ酸配列との同一性が少なくとも約５０．０％のアミノ酸配列であって、単離されたアミノ酸配列がＴｏｌｌ様受容体５（ＴＬＲ５）を活性化する、アミノ酸配列である。配列番号２９に対する同一性が、たとえば、少なくとも約５０．０％、少なくとも約６０．０％、少なくとも約７０．０％、少なくとも約８０．０％、少なくとも約８５．０％、少なくとも約８８．０％、少なくとも約９０．０％、少なくとも約９５．０％、少なくとも約９８．０％または少なくとも約９９．０％のアミノ酸配列を、本発明の組成物、融合タンパク質、方法に使用可能である。配列番号２９に対する同一性が少なくとも約５０．０％の代表的なアミノ酸配列として、配列番号７７０〜７７５があげられる。
Ｔｏｌｌ様受容体５を活性化する本明細書に記載のアミノ酸配列（配列番号２９、３０、３１、３２、３３など）に対する同一性を有するアミノ酸配列に関して本明細書で使用する場合の「連続的な」とは、同一率を共有するアミノ酸配列のどこにも挿入または欠失のないアミノ酸配列を示す。たとえば、配列番号２９に対する同一性が少なくとも５０％であるアミノ酸配列は、配列番号２９と比較したときにアミノ酸配列にギャップ（すなわち欠失）がなく、配列番号２９と比較したときにアミノ酸配列に対する追加のアミノ酸（すなわち挿入）もない。
もうひとつの実施形態では、本発明は、任意の挿入または配列番号３０からの任意の欠失を含めて配列番号３０（Ｒ３Ｄ０コンストラクト）に示す連続的なアミノ酸配列との同一性が少なくとも約５０．０％のアミノ酸配列であって、単離されたアミノ酸配列がＴｏｌｌ様受容体５を活性化する、アミノ酸配列である。配列番号３０に対する同一性が少なくとも約５０．０％の代表的なアミノ酸配列として、配列番号７７６〜７８１があげられる。
別の実施形態では、本発明は、任意の挿入または配列番号３１からの任意の欠失を含めて配列番号３１（Ｄ３Ｎコンストラクト）に示す連続的なアミノ酸配列との同一性が少なくとも約６０．０％のアミノ酸配列であり、単離されたアミノ酸配列がＴｏｌｌ様受容体５を活性化する、アミノ酸配列である。配列番号３１に対する同一性が少なくとも約６０．０％の代表的なアミノ酸配列として、配列番号７８２〜７８７があげられる。
さらにもうひとつの実施形態では、本発明は、任意の挿入または配列番号３２からの任意の欠失を含めて配列番号３２（Ｄ３ＮＣｓコンストラクト）に示す連続的なアミノ酸配列との同一性が少なくとも約６０．０％であるアミノ酸配列であって、単離されたアミノ酸配列がＴｏｌｌ様受容体５を活性化する、アミノ酸配列である。配列番号３２に対する同一性が少なくとも約６０．０％の代表的なアミノ酸配列として、配列番号７８８〜７９３があげられる。
もうひとつの実施形態では、本発明は、任意の挿入または配列番号３３からの任意の欠失を含めて配列番号３３（Ｄ１コンストラクト）に示す連続的なアミノ酸配列との同一性が少なくとも約６０．０％のアミノ酸配列であって、単離されたアミノ酸配列がＴｏｌｌ様受容体５を活性化する、アミノ酸配列である。配列番号３３に対する同一性が少なくとも約６０．０％の代表的なアミノ酸配列として、配列番号７９４〜７９９があげられる。
Claims (3)
- 任意の挿入または配列番号２９からの任意の欠失を含む、配列番号２９に示す連続的なアミノ酸配列との同一性が少なくとも約５０．０％であるポリぺプチドであって、Ｔｏｌｌ様受容体５を活性化する、ポリペプチド。
- 配列番号２９に示すアミノ酸配列の少なくとも１つおよび少なくとも１つの抗原の少なくとも一部が、Ｔｏｌｌ様受容体５を活性化する融合タンパク質の構成要素であり、抗原が配列番号２９のアミノ酸残基１９０と１９１の間にある、請求項１記載のポリぺプチド。
- 配列番号２９に示すアミノ酸配列の少なくとも１つおよび少なくとも２つの抗原の少なくとも一部が、Ｔｏｌｌ様受容体５を活性化する融合タンパク質の構成要素であり、少なくとも１つの抗原が配列番号２９のアミノ酸残基１９０と１９１の間にあり、少なくとも１つの他の抗原が配列番号２９のアミノ酸残基４０５に融合されている、請求項１記載のポリぺプチド。
Applications Claiming Priority (21)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12460408P | 2008-04-18 | 2008-04-18 | |
| US12461708P | 2008-04-18 | 2008-04-18 | |
| US12467008P | 2008-04-18 | 2008-04-18 | |
| US61/124,617 | 2008-04-18 | ||
| US61/124,670 | 2008-04-18 | ||
| US61/124,604 | 2008-04-18 | ||
| US12566008P | 2008-04-25 | 2008-04-25 | |
| US61/125,660 | 2008-04-25 | ||
| US12699308P | 2008-05-08 | 2008-05-08 | |
| US12697808P | 2008-05-08 | 2008-05-08 | |
| US61/126,993 | 2008-05-08 | ||
| US61/126,978 | 2008-05-08 | ||
| US13259408P | 2008-06-20 | 2008-06-20 | |
| US61/132,594 | 2008-06-20 | ||
| US13784008P | 2008-08-04 | 2008-08-04 | |
| US61/137,840 | 2008-08-04 | ||
| US19979308P | 2008-11-19 | 2008-11-19 | |
| US61/199,793 | 2008-11-19 | ||
| US20035408P | 2008-11-26 | 2008-11-26 | |
| US61/200,354 | 2008-11-26 | ||
| PCT/US2009/002428 WO2009128950A2 (en) | 2008-04-18 | 2009-04-17 | Deletion mutants of flagellin and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011519828A JP2011519828A (ja) | 2011-07-14 |
| JP2011519828A5 true JP2011519828A5 (ja) | 2012-07-12 |
Family
ID=40888246
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011505037A Pending JP2011519828A (ja) | 2008-04-18 | 2009-04-17 | フラジェリンの欠失変異体と使用方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US8932605B2 (ja) |
| EP (2) | EP2280991B1 (ja) |
| JP (1) | JP2011519828A (ja) |
| CN (1) | CN104080475A (ja) |
| AU (1) | AU2009236585B2 (ja) |
| CA (1) | CA2721246A1 (ja) |
| ES (1) | ES2594102T3 (ja) |
| SG (1) | SG190562A1 (ja) |
| WO (4) | WO2009128949A2 (ja) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008527009A (ja) | 2005-01-19 | 2008-07-24 | バクシネート コーポレーション | 病原体関連分子パターンおよび抗原を含む組成物ならびに免疫応答を刺激するためのそれらの使用 |
| AU2007224034B2 (en) | 2006-03-07 | 2012-03-29 | Vaxinnate Corporation | Compositions that include hemagglutinin, methods of making and methods of use thereof |
| GB0720250D0 (en) * | 2007-10-17 | 2007-11-28 | Univ Edinburgh | Immunogenic compositions containing escherichia coli h7 flagella and methods of use thereof |
| WO2009128949A2 (en) | 2008-04-18 | 2009-10-22 | Vaxinnate Corporation | Compositions of dengue viral proteins and methods of use |
| EP2300609B1 (en) | 2008-06-25 | 2013-11-20 | INSERM - Institut National de la Santé et de la Recherche Médicale | Novel immunoadjuvant flagellin-based compounds and use thereof |
| EP4218799A1 (en) | 2009-07-15 | 2023-08-02 | GlaxoSmithKline Biologicals S.A. | Rsv f protein compositions and methods for making same |
| CN102002098B (zh) * | 2009-11-27 | 2013-07-24 | 中国科学院武汉病毒研究所 | 一种改造的鞭毛素蛋白及其制备方法和应用 |
| AU2011203740B2 (en) * | 2010-01-06 | 2014-11-13 | Vaxinnate Corporation | Methods and compositions for providing protective immunity in the elderly |
| ES2769326T3 (es) | 2010-02-05 | 2020-06-25 | Univ Cornell | Métodos y composiciones para la inmunoterapia contra el cáncer usando células tumorales que expresan la proteína de fusión de flagelina y antígeno asociado al tumor |
| EP2571990A4 (en) * | 2010-05-21 | 2013-11-20 | Univ Pittsburgh | UNIVERSAL DENGUE VIRUS SEQUENCES AND METHOD FOR THEIR USE |
| BR112013018845A2 (pt) * | 2011-01-28 | 2016-07-19 | Medimmune Llc | expressão de glicoproteínas de fusão viral solúveis em células de mamífero |
| WO2012115715A2 (en) * | 2011-02-21 | 2012-08-30 | Vaxinnate Corporation | Compositions with enhanced immunogenicity and/or reduced reactogenicity and methods of use |
| EP2681246A4 (en) * | 2011-02-28 | 2015-05-06 | Vaxinnate Corp | VACCINE AGAINST DENGUE TATRAVALENT AND MIXED BIVALENT |
| GB201112091D0 (en) | 2011-07-14 | 2011-08-31 | Gt Biolog Ltd | Bacterial strains isolated from pigs |
| WO2013019604A2 (en) * | 2011-07-29 | 2013-02-07 | Georgia State University Research Foundation, Inc. | Protein production method |
| GB201117313D0 (en) | 2011-10-07 | 2011-11-16 | Gt Biolog Ltd | Bacterium for use in medicine |
| KR102373828B1 (ko) * | 2011-10-12 | 2022-03-14 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | 인간 파필로마 바이러스에 대한 백신 및 이것을 사용하는 방법 |
| GB201120000D0 (en) | 2011-11-20 | 2012-01-04 | Glaxosmithkline Biolog Sa | Vaccine |
| GB201119999D0 (en) | 2011-11-20 | 2012-01-04 | Glaxosmithkline Biolog Sa | Vaccine |
| US9296792B2 (en) * | 2012-05-23 | 2016-03-29 | The Board Of Trustees Of The Leland Stanford Junior University | Ordered flagellin array as an immunostimulant |
| AU2013295242C1 (en) | 2012-07-27 | 2018-08-09 | Institut National De La Sante Et De La Recherche Medicale | CD147 as receptor for pilus-mediated adhesion of meningococci to vascular endothelia |
| US8932598B2 (en) * | 2012-08-28 | 2015-01-13 | Vaxinnate Corporation | Fusion proteins and methods of use |
| CN105101951B (zh) * | 2012-10-29 | 2021-08-03 | 新加坡科技研究局 | 一种用于基因-药物治疗的新型试剂 |
| PL2950886T3 (pl) * | 2013-02-01 | 2020-06-01 | Medimmune, Llc | Epitopy białka F syncytialnego wirusa oddechowego |
| WO2014130921A1 (en) | 2013-02-25 | 2014-08-28 | Particle Sciences, Inc. | Particle formulations for delivery of tlr agonists and antigens |
| WO2014168948A2 (en) | 2013-04-09 | 2014-10-16 | Vaxinnate Corporation | Clostridium difficile compositions and methods of use |
| GB201306536D0 (en) * | 2013-04-10 | 2013-05-22 | Gt Biolog Ltd | Polypeptide and immune modulation |
| WO2015070925A1 (en) * | 2013-11-15 | 2015-05-21 | Biomay Ag | Fusion proteins |
| CA2934472A1 (en) * | 2014-01-09 | 2015-07-16 | Alpha-O Peptides Ag | Flagellin-containing protein nanoparticles as a vaccine platform |
| DE102014005647B4 (de) * | 2014-01-30 | 2016-05-12 | Klaus-Dieter Beller | Pulverinhalator und Pulverinhalatorset |
| DE102014005646B4 (de) * | 2014-01-30 | 2016-05-12 | Klaus-Dieter Beller | Pulverinhalator und Pulverinhalationsset |
| US10821175B2 (en) | 2014-02-25 | 2020-11-03 | Merck Sharp & Dohme Corp. | Lipid nanoparticle vaccine adjuvants and antigen delivery systems |
| PL235555B1 (pl) | 2014-06-24 | 2020-09-07 | Inst Biotechnologii I Antybiotykow | Wyizolowany i oczyszczony polipeptyd hemaglutyniny (HA ) wirusa grypy H5N1, kompozycja zawierająca polipeptyd i jej zastosowanie, przeciwciało wiążące się specyficznie z polipeptydem oraz sposób otrzymywania tego polipeptydu |
| WO2016014899A1 (en) * | 2014-07-25 | 2016-01-28 | Cleveland Biolabs, Inc. | Flagellin derivatives and uses |
| US20160030349A1 (en) * | 2014-08-01 | 2016-02-04 | Boehringer Ingelheim Vetmedica Gmbh | Nanoparticles, methods of preparation, and uses thereof |
| NO3065748T3 (ja) | 2014-12-23 | 2018-04-21 | ||
| SI3193901T1 (en) | 2014-12-23 | 2018-06-29 | 4D Pharma Research Limited | Pirin polypeptide and immune modulation |
| WO2016130786A2 (en) * | 2015-02-15 | 2016-08-18 | Integral Molecular, Inc. | Flaviviridae proteins and virions and methods of use thereof |
| MA41060B1 (fr) | 2015-06-15 | 2019-11-29 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| SG10201912324XA (en) | 2015-06-15 | 2020-02-27 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| HUE044617T2 (hu) | 2015-06-15 | 2019-11-28 | 4D Pharma Res Ltd | Baktériumtörzseket tartalmazó készítmények |
| ME03563B (me) | 2015-06-15 | 2020-07-20 | 4D Pharma Res Ltd | Kompozicije koje sadrže bakterijske sojeve |
| MA41010B1 (fr) | 2015-06-15 | 2020-01-31 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| WO2016205641A2 (en) * | 2015-06-17 | 2016-12-22 | Research Institute At Nationwide Children's Hospital | Respiratory syncytial virus having cleavage-resistant g protein and related materials and methods |
| WO2017031280A1 (en) * | 2015-08-20 | 2017-02-23 | Vaxinnate Corporation | Fusion proteins that include dengue antigens and methods of use |
| GB201520497D0 (en) | 2015-11-20 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| MD3209310T2 (ro) | 2015-11-20 | 2018-06-30 | 4D Pharma Res Ltd | Compoziții care conțin tulpini bacteriene |
| GB201520631D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| GB201520638D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| GB201612191D0 (en) | 2016-07-13 | 2016-08-24 | 4D Pharma Plc | Compositions comprising bacterial strains |
| CN114712405A (zh) | 2016-03-04 | 2022-07-08 | 4D制药有限公司 | 包含细菌菌株的组合物 |
| JP2019517522A (ja) * | 2016-06-03 | 2019-06-24 | エトゥビクス コーポレーション | ヒトパピローマウイルス（ｈｐｖ）関連疾患の処置のための組成物及び方法 |
| TWI802545B (zh) | 2016-07-13 | 2023-05-21 | 英商４Ｄ製藥有限公司 | 包含細菌菌株之組合物 |
| JP6655736B2 (ja) * | 2016-10-31 | 2020-02-26 | ウーハン サンリ バイオテクノロジー シーオー．，エルティーディー．Ｗｕｈａｎ Ｓａｎｌｉ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ Ｃｏ．， Ｌｔｄ． | 呼吸器合胞体ウイルスワクチン |
| GB201621123D0 (en) | 2016-12-12 | 2017-01-25 | 4D Pharma Plc | Compositions comprising bacterial strains |
| EP3630137B1 (en) | 2017-05-22 | 2023-05-17 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| MA41708A (fr) | 2017-05-24 | 2020-04-08 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| KR101911235B1 (ko) | 2017-05-29 | 2018-10-24 | 건국대학교 산학협력단 | Stf2 재조합 단백질 발현용 유전자 카세트 |
| PL3600364T3 (pl) | 2017-06-14 | 2021-01-11 | 4D Pharma Research Limited | Kompozycje zawierające szczep bakteryjny z rodzaju megasphaera i ich zastosowania |
| SI3638271T1 (sl) | 2017-06-14 | 2021-01-29 | 4D Pharma Research Limited | Sestavki, ki vsebujejo bakterijske seve |
| AU2018304469B2 (en) | 2017-07-20 | 2023-04-06 | Spogen Biotech Inc. | Bioactive polypeptides for improvements in plant protection, growth and productivity |
| WO2019066437A1 (ko) * | 2017-09-29 | 2019-04-04 | 에스케이바이오사이언스 주식회사 | 가용성 변형 호흡기 융합세포 바이러스 (rsv) ｆ 단백질 항원 |
| EP3581201A1 (en) | 2018-06-15 | 2019-12-18 | GlaxoSmithKline Biologicals S.A. | Escherichia coli o157:h7 proteins and uses thereof |
| KR20200050264A (ko) * | 2018-11-01 | 2020-05-11 | 에스케이바이오사이언스(주) | 재조합 호흡기 세포융합 바이러스 f 단백질 및 이를 포함하는 백신 조성물 |
| CN111793591B (zh) * | 2020-06-22 | 2022-11-25 | 南昌大学 | 一株高效刺激免疫反应的沙门菌突变株及构建方法和应用 |
| EP4255919A2 (en) | 2020-12-02 | 2023-10-11 | GlaxoSmithKline Biologicals S.A. | Donor strand complemented fimh |
| WO2023235660A2 (en) * | 2022-05-17 | 2023-12-07 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Flavivirus immunogens and vaccine compositions and methods of using the same |
Family Cites Families (111)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL61904A (en) | 1981-01-13 | 1985-07-31 | Yeda Res & Dev | Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same |
| US4659669A (en) | 1981-03-02 | 1987-04-21 | Regents Of The Univ. Of California | Microbial expression of human influenza hemagglutinin proteins |
| US4533254A (en) | 1981-04-17 | 1985-08-06 | Biotechnology Development Corporation | Apparatus for forming emulsions |
| US4625015A (en) | 1982-08-23 | 1986-11-25 | Scripps Clinic & Research Foundation | Broad spectrum influenza antisera |
| US6090406A (en) | 1984-04-12 | 2000-07-18 | The Liposome Company, Inc. | Potentiation of immune responses with liposomal adjuvants |
| US4728575A (en) | 1984-04-27 | 1988-03-01 | Vestar, Inc. | Contrast agents for NMR imaging |
| US4752473A (en) | 1984-10-12 | 1988-06-21 | The Regents Of The University Of California | Expression of glycosylated human influenza hemagglutinin proteins |
| US4753788A (en) | 1985-01-31 | 1988-06-28 | Vestar Research Inc. | Method for preparing small vesicles using microemulsification |
| IL78775A (en) | 1985-05-15 | 1992-06-21 | Biotech Australia Pty Ltd | Oral vaccines |
| US4737323A (en) | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
| US4728578A (en) | 1986-08-13 | 1988-03-01 | The Lubrizol Corporation | Compositions containing basic metal salts and/or non-Newtonian colloidal disperse systems and vinyl aromatic containing polymers |
| WO1988001873A1 (en) | 1986-09-22 | 1988-03-24 | Emory University | Vaccine and method of preparation |
| NZ219515A (en) | 1987-02-10 | 1989-09-27 | Wellcome Found | Fusion proteins comprising influenza virus ha and a nonnatural antigenic epitope |
| NZ219516A (en) | 1987-02-10 | 1991-02-26 | Wellcome Found | Fusion proteins of hbcag (hepatitis b virus core antigen) |
| US6130082A (en) | 1988-05-05 | 2000-10-10 | American Cyanamid Company | Recombinant flagellin vaccines |
| WO1989010967A1 (en) | 1988-05-05 | 1989-11-16 | Praxis Biologics, Inc. | Recombinant flagellin vaccines |
| US4935171A (en) | 1989-01-27 | 1990-06-19 | Vestar, Inc. | Method for vesicle formation |
| US5709879A (en) | 1990-06-29 | 1998-01-20 | Chiron Corporation | Vaccine compositions containing liposomes |
| CH683101A5 (de) | 1990-09-18 | 1994-01-14 | Biotech Australia Pty Ltd | T-Zellen-Epitope. |
| US5290686A (en) | 1991-07-31 | 1994-03-01 | The United States Of America As Represented By The Department Of Health And Human Services | Expression of influenza a M2 protein in baculovirus |
| AU681572B2 (en) | 1991-10-21 | 1997-09-04 | Med Immune, Inc. | Bacterial expression vectors containing DNA encoding secretion signals of lipoproteins |
| US5877289A (en) | 1992-03-05 | 1999-03-02 | The Scripps Research Institute | Tissue factor compositions and ligands for the specific coagulation of vasculature |
| IL101639A0 (en) | 1992-04-17 | 1992-12-30 | Yeda Res & Dev | Recombinant influenza vaccines |
| FR2695563B1 (fr) | 1992-09-11 | 1994-12-02 | Pasteur Institut | Microparticules portant des antigènes et leur utilisation pour l'induction de réponses humorales ou cellulaires. |
| EP0621339B1 (en) | 1992-09-17 | 2001-10-24 | Takara Shuzo Co. Ltd. | Immunogenic human influenza A virus haemagglutinin polypeptides |
| US6337070B1 (en) | 1993-04-29 | 2002-01-08 | Takara Shuzo Co., Ltd. | Polypeptides for use in generating anti-human influenza virus antibodies |
| US5464933A (en) * | 1993-06-07 | 1995-11-07 | Duke University | Synthetic peptide inhibitors of HIV transmission |
| US5976552A (en) | 1995-04-28 | 1999-11-02 | Protein Sciences Corporation | Virus vaccines |
| US5762939A (en) | 1993-09-13 | 1998-06-09 | Mg-Pmc, Llc | Method for producing influenza hemagglutinin multivalent vaccines using baculovirus |
| ES2370937T3 (es) | 1993-09-13 | 2011-12-23 | Protein Sciences Corporation | Un método para producir vacunas antigripales polivalentes a base de hemaglutinina. |
| PT733113E (pt) | 1994-01-11 | 2007-08-10 | Vlaams Interuniv Inst Biotech | Vacina contra a gripe |
| US6764682B1 (en) * | 1994-06-16 | 2004-07-20 | Aventis Pasteur Limited | Adjuvant compositions containing more than one adjuvant |
| US5612037A (en) | 1994-07-26 | 1997-03-18 | Connaught Laboratories, Inc. | Influenza virus subunit conjugates |
| US6132764A (en) | 1994-08-05 | 2000-10-17 | Targesome, Inc. | Targeted polymerized liposome diagnostic and treatment agents |
| US5512294A (en) | 1994-08-05 | 1996-04-30 | Li; King C. | Targeted polymerized liposome contrast agents |
| US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| FR2723849B1 (fr) | 1994-08-31 | 1997-04-11 | Biovector Therapeutics Sa | Procede pour augmenter l'immunogenicite, produit obtenu et composition pharmaceutique |
| NZ306316A (en) | 1995-04-17 | 2001-06-29 | Smithkline Beecham Biolog S | use of lipoprotein and a type 2T independent antigen to induce an immune response to the antigen |
| SE9604322D0 (sv) | 1996-11-25 | 1996-11-25 | Astra Ab | Bacterial antigens and vaccine compositions II |
| JP5087758B2 (ja) | 1997-03-10 | 2012-12-05 | オタワ ホスピタル リサーチ インスティチュート | アジュバントとして非メチル化ＣｐＧジヌクレオチドを含む核酸の使用 |
| ATE309378T1 (de) | 1997-04-18 | 2005-11-15 | Biotechnolog Forschung Gmbh | Abgeschwächter salmonellenstamm, gebraucht als vehikel zur oralen immunisierung |
| EP0986572B2 (en) | 1997-06-06 | 2007-06-13 | Dynavax Technologies Corporation | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
| US7731972B1 (en) | 2000-02-04 | 2010-06-08 | Vlaams Interuniversitair Instituut Voor Biotechnologie | Immunoprotective influenza antigen and its use in vaccination |
| EP0996717B1 (en) | 1997-08-05 | 2005-12-07 | Vlaams Interuniversitair Instituut voor Biotechnologie vzw. | Immunoprotective influenza antigen and its use in vaccination |
| US6169175B1 (en) | 1997-08-06 | 2001-01-02 | Centers For Disease Control And Prevention | Preparation and use of recombinant influenza A virus M2 construct vaccines |
| US6060308A (en) * | 1997-09-04 | 2000-05-09 | Connaught Laboratories Limited | RNA respiratory syncytial virus vaccines |
| AU754065B2 (en) | 1997-09-29 | 2002-11-07 | Macfarlane Burnet Institute For Medical Research And Public Health Ltd | Mannose receptor bearing cell line and antigen composition |
| US6440736B1 (en) | 1998-10-16 | 2002-08-27 | U-Bisys B.V. | Altering the properties of cells or of particles with membranes derived from cells by means of lipid-modified proteinaceous molecules |
| US6086881A (en) | 1998-05-15 | 2000-07-11 | Children's Medical Center Corp. | Spatially aligned conjugated composition having a thioether bond linkage |
| TWI229679B (en) | 1998-06-20 | 2005-03-21 | United Biomedical Inc | Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens |
| IL127331A0 (en) | 1998-11-30 | 1999-09-22 | Yeda Res & Dev | Peptide-based vaccine for influenza |
| WO2001040280A2 (en) | 1999-11-29 | 2001-06-07 | Inotek Corporation | Composition and method for treating a microbial infection |
| EP1237911A2 (en) * | 1999-12-06 | 2002-09-11 | Whitehead Institute For Biomedical Research | Inhibition of hrsv membrane fusion |
| CA2400495A1 (en) | 2000-02-18 | 2001-08-23 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Use of opri lipoprotein from pseudomonas as a th1 inducing natural adjuvant for heterologous antigens |
| AU2001264824A1 (en) * | 2000-06-01 | 2001-12-11 | St. Jude Children's Research Hospital | Vaccine and gene therapy vector and methods of use thereof |
| IL153290A0 (en) | 2000-06-23 | 2003-07-06 | American Cyanamid Co | Assembly of wild-type and chimeric influenza virus-like particles (vlps) |
| US20020061312A1 (en) | 2000-07-31 | 2002-05-23 | Ruslan Medzhitov | Innate immune system-directed vaccines |
| WO2002009748A1 (en) | 2000-07-31 | 2002-02-07 | Yale University | Innate immune system-directed vaccines |
| US20030232055A1 (en) | 2000-07-31 | 2003-12-18 | Ruslan Medzhitov | Innate immune system-directed vaccines |
| AU2002224416A1 (en) * | 2000-10-18 | 2002-04-29 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention | Compositions and methods for modulating RSV infection and immunity |
| US20040161846A1 (en) * | 2000-11-22 | 2004-08-19 | Mason Anthony John | Method of expression and agents identified thereby |
| US20030175287A1 (en) | 2001-01-03 | 2003-09-18 | Yale University | Innate immune system-directed vaccines |
| US7449188B2 (en) | 2001-01-18 | 2008-11-11 | Vlaams Interuniversitair Instituut Voor Biotechnologie | Recombinant oligometric protein complexes with enhanced immunogenic potential |
| US8703146B2 (en) | 2001-04-20 | 2014-04-22 | Institute For Systems Biology | Toll-like receptor 5 ligands and methods of use |
| WO2002085933A1 (en) | 2001-04-20 | 2002-10-31 | The Institute For Systems Biology | Toll-like receptor 5 ligands and methods of use |
| US7361352B2 (en) | 2001-08-15 | 2008-04-22 | Acambis, Inc. | Influenza immunogen and vaccine |
| US20030175863A1 (en) | 2001-08-15 | 2003-09-18 | Birkett Ashley J. | Influenza immunogen and vaccine |
| JP4516748B2 (ja) | 2001-09-14 | 2010-08-04 | サイトス バイオテクノロジー アーゲー | ウィルス様粒子中への免疫賦活物質のパッケージ化：調製法および使用法 |
| AU2002361682A1 (en) | 2001-12-14 | 2003-06-30 | Elizabeth Kopp | Innate immune system-directed vaccines |
| AU2003213168A1 (en) | 2002-02-21 | 2003-12-19 | Apovia, Inc. | IMMUNOGENIC HBc CHIMER PARTICLES STABILIZED WITH AN N-TERMINAL CYSTEINE |
| US7285289B2 (en) | 2002-04-12 | 2007-10-23 | Nagy Jon O | Nanoparticle vaccines |
| WO2004076621A2 (en) | 2003-02-27 | 2004-09-10 | Yeda Research And Development Co. Ltd. | Compositions of nucleic acids for treating and detecting influenza virus |
| BRPI0407877A (pt) | 2003-03-07 | 2006-03-01 | Merck & Co Inc | conjugado de peptìdeo-proteìna, vacina para a prevenção ou melhora da infecção pelo vìrus influenza, e, método para induzir um resposta imune em um paciente |
| US8592197B2 (en) | 2003-07-11 | 2013-11-26 | Novavax, Inc. | Functional influenza virus-like particles (VLPs) |
| WO2005042564A1 (en) * | 2003-10-20 | 2005-05-12 | Sidney Kimmel Cancer Center | Flagellin fusion proteins as adjuvants or vaccines and methods of use |
| EP1697511A4 (en) * | 2003-12-11 | 2007-11-21 | Vaxdesign Corp | IMMUNOTHERAPY COMPOSITIONS, METHODS FOR PREPARING AND USING THE SAME |
| WO2005077408A2 (en) | 2004-02-06 | 2005-08-25 | Vaxinnate Corporation | Compositions of pamps and listeria monocytogenes and methods of use |
| US7700720B2 (en) * | 2004-09-21 | 2010-04-20 | Medimmune, Llc | Antibodies against and methods for producing vaccines for respiratory syncytial virus |
| US7404963B2 (en) | 2004-10-01 | 2008-07-29 | The University Of South Florida | Flagellin-based adjuvants and vaccines |
| DE102004049223A1 (de) | 2004-10-08 | 2006-04-20 | Johannes-Gutenberg-Universität Mainz | Zubereitung zum Impfen, Impfverfahren und Verwendung einer Impf-Zubereitung |
| CA2587084C (en) * | 2004-10-08 | 2019-07-16 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention | Modulation of replicative fitness by using less frequently used synonym ous codons |
| TW200636064A (en) * | 2004-10-28 | 2006-10-16 | Centocor Inc | Anti-respiratory syncytial virus antibodies, antigens and uses thereof |
| WO2006066214A2 (en) | 2004-12-16 | 2006-06-22 | Wake Forest University Health Sciences | Use of flagellin in the immunotherapy of yersinia pestis |
| US20090162400A1 (en) | 2004-12-21 | 2009-06-25 | Powell Thomas J | Compositions of influenza viral proteins and methods of use thereof |
| NZ556004A (en) | 2004-12-21 | 2010-05-28 | Vaxinnate Corp | Compositions of influenza viral proteins comprising at least one flagellin and at least one influenza M2 protein |
| HU227285B1 (en) * | 2004-12-29 | 2011-01-28 | Mta Enzimologiai Intezet | Modified flagellins and flagellar filaments useful as receptors and processes for producing same |
| JP2008527009A (ja) | 2005-01-19 | 2008-07-24 | バクシネート コーポレーション | 病原体関連分子パターンおよび抗原を含む組成物ならびに免疫応答を刺激するためのそれらの使用 |
| US20090068224A1 (en) | 2005-01-31 | 2009-03-12 | Vaxinnate Corporation | Method to identify polypeptide toll-like receptor (tlr) ligands |
| US20090028889A1 (en) | 2005-01-31 | 2009-01-29 | Vaxinnate Corporation | Novel Polypeptide Ligands For Toll-Like Receptor 2 (TLR2) |
| US20090081253A1 (en) | 2005-03-23 | 2009-03-26 | Glaxosmithkline Biologicals S.A. | Composition |
| AU2006234847A1 (en) * | 2005-04-08 | 2006-10-19 | Medimmune, Llc | Antibodies against mammalian metapneumovirus |
| AU2006279323B2 (en) | 2005-08-16 | 2013-08-01 | Merck Sharp & Dohme Corp. | Influenza recombinant subunit vaccine |
| CU23578A1 (es) * | 2005-09-16 | 2010-09-30 | Ct Ingenieria Genetica Biotech | Proteína de la cápsida del virus dengue inductora de respuesta protectora y composición vacunal |
| US20070111331A1 (en) * | 2005-11-16 | 2007-05-17 | Chin-Yih Rex Hong | Diagnostic methods using magnetic nanoparticles |
| DK1968632T3 (da) | 2005-12-06 | 2012-07-16 | Yeda Res & Dev | Forbedret influenzavaccine |
| EP1976559B3 (en) | 2006-01-27 | 2020-02-19 | Seqirus UK Limited | Influenza vaccines containing hemagglutinin and matrix proteins |
| AU2007224034B2 (en) | 2006-03-07 | 2012-03-29 | Vaxinnate Corporation | Compositions that include hemagglutinin, methods of making and methods of use thereof |
| JP2009533455A (ja) | 2006-04-12 | 2009-09-17 | マサチューセッツ インスティテュート オブ テクノロジー | 癒着を阻害するための組成物および方法 |
| KR101180885B1 (ko) * | 2006-04-19 | 2012-09-10 | 포항공과대학교 산학협력단 | 자궁경부암의 예방 및 치료를 위한 사람 파필로마바이러스폴리펩타이드와 면역 증강제를 포함하는 조성물 |
| WO2007125535A1 (en) * | 2006-05-01 | 2007-11-08 | Biondvax Pharmaceuticals Ltd. | Recombinant flagellin gene and uses thereof |
| WO2008010478A1 (fr) | 2006-07-21 | 2008-01-24 | Yokohama City University | Vaccin contre un mutant de la flagelline |
| DK2173376T3 (en) | 2007-08-02 | 2015-06-29 | Biondvax Pharmaceuticals Ltd | Multimeric multi-epitope influenza vaccines |
| WO2009073133A1 (en) * | 2007-11-29 | 2009-06-11 | Vaxinnate Corporation | Compositions of toll-like receptor agonists and papillomavirus antigens and uses thereof |
| WO2009082440A2 (en) | 2007-12-18 | 2009-07-02 | Vaxinnate Corporation | Compositions of toll-like receptor agonists and malaria antigens and methods of use |
| WO2009128949A2 (en) | 2008-04-18 | 2009-10-22 | Vaxinnate Corporation | Compositions of dengue viral proteins and methods of use |
| CN102046198A (zh) | 2008-04-25 | 2011-05-04 | 系统生物学研究所 | 鞭毛蛋白多肽疫苗 |
| AU2011203740B2 (en) | 2010-01-06 | 2014-11-13 | Vaxinnate Corporation | Methods and compositions for providing protective immunity in the elderly |
| WO2012115715A2 (en) | 2011-02-21 | 2012-08-30 | Vaxinnate Corporation | Compositions with enhanced immunogenicity and/or reduced reactogenicity and methods of use |
| EP2681246A4 (en) | 2011-02-28 | 2015-05-06 | Vaxinnate Corp | VACCINE AGAINST DENGUE TATRAVALENT AND MIXED BIVALENT |
| WO2013066365A1 (en) | 2011-11-04 | 2013-05-10 | Vaxinnate Corporation | Immunologic constructs and methods |
| US8932598B2 (en) | 2012-08-28 | 2015-01-13 | Vaxinnate Corporation | Fusion proteins and methods of use |
-
2009
- 2009-04-17 WO PCT/US2009/002427 patent/WO2009128949A2/en active Application Filing
- 2009-04-17 AU AU2009236585A patent/AU2009236585B2/en not_active Ceased
- 2009-04-17 WO PCT/US2009/002429 patent/WO2009128951A2/en active Application Filing
- 2009-04-17 WO PCT/US2009/002428 patent/WO2009128950A2/en active Application Filing
- 2009-04-17 EP EP09732473.5A patent/EP2280991B1/en not_active Not-in-force
- 2009-04-17 JP JP2011505037A patent/JP2011519828A/ja active Pending
- 2009-04-17 SG SG2013029319A patent/SG190562A1/en unknown
- 2009-04-17 CA CA2721246A patent/CA2721246A1/en not_active Abandoned
- 2009-04-17 WO PCT/US2009/002430 patent/WO2009128952A2/en active Application Filing
- 2009-04-17 ES ES09732473.5T patent/ES2594102T3/es active Active
- 2009-04-17 EP EP16163252.6A patent/EP3115060A1/en not_active Withdrawn
- 2009-04-17 CN CN200980122596.XA patent/CN104080475A/zh active Pending
-
2010
- 2010-10-15 US US12/905,584 patent/US8932605B2/en not_active Expired - Fee Related
-
2014
- 2014-12-16 US US14/572,415 patent/US9205138B2/en not_active Expired - Fee Related
- 2014-12-17 US US14/574,058 patent/US9211320B2/en not_active Expired - Fee Related
-
2015
- 2015-11-04 US US14/932,355 patent/US20160193329A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011519828A5 (ja) | ||
| WO2008022759A3 (en) | Specific and high affinity binding proteins comprising modified sh3 domains of fyn kinase | |
| JP2019514361A5 (ja) | ||
| RU2017101436A (ru) | Mic-1 слитные белки и их применение | |
| EA201100070A1 (ru) | Туберкулезный белок rv2386c, композиции и их применения | |
| PE20141727A1 (es) | Composiciones, usos y metodos para tratamiento de trastornos y enfermedades metabolicas | |
| HRP20221531T1 (hr) | Pripravci faktora viii i postupci dobivanja i korištenja istih | |
| MX2009004147A (es) | Vacunas de peptido para canceres que expresan polipeptidos mphosph1 o depdc1. | |
| WO2011123813A3 (en) | Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same | |
| IL199263A (en) | Glucagon peptide with enhanced solubility, pharmaceutical composition containing it and its uses for drug preparation | |
| EP2594582A3 (en) | Peptide vaccines with Seq Id No: 110, 111, 387, 112, 394 114, 116, 117 or 121 for cancers expressing tumor-associated antigens | |
| WO2009046220A3 (en) | Lipopeptides for delivery of nucleic acids | |
| EA200870237A1 (ru) | Последовательности пептидов и композиции | |
| PE20140986A1 (es) | Proteinas de fusion y vacunas de combinacion que comprenden proteina e y pilina a de haemophilus influenzae | |
| MX343386B (es) | Proteinas de fusion portadoras de peptido como vacunas para alergia. | |
| IN2012DN03368A (ja) | ||
| UA107330C2 (uk) | Туберкульозний білок rv3616c та його застосування | |
| MX2011008759A (es) | Medios y metodos para fabricar neurotoxina altamente pura. | |
| BR112017017609A2 (ja) | Fc fusion quantity compatibility IgE receptor alpha chain | |
| JP2019535321A5 (ja) | ||
| WO2010007144A3 (en) | Mutated netrin-4 proteins, fragments thereof and their uses as drugs | |
| MX2009007261A (es) | Vacuna de peptido foxp3. | |
| WO2007089038A8 (ja) | 新規ホスホリパーゼｄ | |
| NZ760789A (en) | Uti fusion proteins | |
| DK2289533T3 (da) | Epitoppeptider afledt af karendothelvækstfaktorreceptor-1 samt vacciner indeholdende disse peptider |